DelveInsight’s Respiratory Syncytial Virus (RSV) Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for the Respiratory Syncytial Virus (RSV) market. The disease summary and Respiratory Syncytial Virus treatment guidelines are included in this complete description of the Respiratory syncytial virus pipeline landscape.
Some Key Highlights from the Respiratory Syncytial Virus Pipeline Report
Pharmaceutical companies such as MedImmune LLC (AstraZeneca), Janssen Sciences Ireland UC, Meissa Vaccines, Inc., ReViral Ltd, Codagenix, Inc, ModernaTX, Inc., Virometix, Vaxart, Inc., and others are among the companies developing new drug candidates to improve the Respiratory Syncytial Virus pipeline landscape.
Respiratory Syncytial Virus pipeline therapies such as MEDI8897 and JNJ-53718678 are in the Phase III of clinical trials while therapies such as MV-012-968 and RV521 are in the Phase II of clinical trials.
CodaVax-RSV, mRNA-1345 and V-306 are among the pipeline therapies for Respiratory Syncytial Virus which are in the Phase I of clinical trials.
Respiratory Syncytial Virus pipeline therapy such as RSV-F is in the early stage of development i.e. early Phase I of clinical trials.
To know more, request sample @ Respiratory Syncytial Virus Pipeline Analysis
Respiratory Syncytial Virus: Overview
The Respiratory Syncytial Virus, or RSV, is a common respiratory virus that causes mild, cold-like symptoms in most people. Although most people recover in a week or two, RSV can be dangerous, particularly for infants and the older adults. In fact, in the United States, RSV is the most prevalent cause of bronchiolitis (inflammation of the tiny airways in the lungs) and pneumonia (lung infection) in children under the age of one year. It’s also a major cause of respiratory problems in the elderly.
Respiratory Syncytial Virus: Symptoms
Runny nose, loss of appetite, coughing, sneezing fever, and wheezing are common symptoms of RSV infection. These signs and symptoms typically occur in stages rather than all at once.
Respiratory Syncytial Virus Pipeline Analysis: Drug Profile
RSVpreF: Pfizer
Product Description
The RSVpreF vaccine candidate is based on the RSV fusion protein’s perfusion form. The vaccination stimulates the development of serum anti-F immunoglobulin G in pregnant women, which can then be passed to the foetus through the placenta and give protection for the first six months of life, when the risk of hospitalization is greatest.
Research and Development in the Respiratory Syncytial Virus Pipeline Landscape
Phase III
NCT04424316: Pfizer began a Phase 3 multicenter, randomised, double-blinded, placebo-controlled study in June 2020 to evaluate the efficacy, safety, and immunogenicity of RSVpreF or placebo (1:1 randomization) in infants born to healthy women who had been vaccinated during pregnancy, as well as the safety and immunogenicity in the pregnant women.
EDP-938: Enanta Pharmaceuticals
Enanta has chosen EDP-938 as its first RSV development candidate because it is a powerful non-fusion inhibitor of both RSV-A and RSV-B activities
Phase II
NCT04633187: Enanta began a Phase 2b, randomised, double-blind, placebo-controlled, multicenter research in December 2020 to assess the efficacy and safety of EDP-938 in Adult Hematopoietic Cell Transplant patients with acute RSV infection and Upper Respiratory Tract symptoms.
Respiratory Syncytial Virus Pipeline Therapies and Key Companies
MEDI8897: MedImmune LLC (AstraZeneca)
JNJ-53718678: Janssen Sciences Ireland UC
MV-012-968: Meissa Vaccines, Inc.
RV521: ReViral Ltd
CodaVax-RSV: Codagenix, Inc
mRNA-1345: ModernaTX, Inc.
V-306: Virometix
RSV-F: Vaxart, Inc.
Reach out for more @Respiratory Syncytial Virus Treatment Landscape
Respiratory Syncytial Virus Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
Protease
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Respiratory Syncytial Virus Key Players: MedImmune LLC (AstraZeneca), Janssen Sciences Ireland UC, Meissa Vaccines, Inc., ReViral Ltd, Codagenix, Inc, ModernaTX, Inc., Virometix, Vaxart, Inc., among others
Respiratory Syncytial Virus Pipeline Therapies: MEDI8897, JNJ-53718678, MV-012-968, RV521, CodaVax-RSV, mRNA-1345, V-306, RSV-F, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Respiratory Syncytial Virus (RSV): Overview
4.
Respiratory Syncytial Virus (RSV)- Analytical Perspective In-depth Commercial Assessment
5.
Pipeline Therapeutics
6.
Late Stage Products (Phase III)
7.
Mid Stage Products (Phase II)
8.
Early Stage Products (Phase I)
9.
Therapeutic Assessment
10.
Inactive Products
11.
Company-University Collaborations (Licensing/Partnering) Analysis
12.
Respiratory Syncytial Virus (RSV) Key Companies
13.
Respiratory Syncytial Virus (RSV) Key Products
14.
Respiratory Syncytial Virus (RSV)- Unmet Needs
15.
Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
16.
Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
17.
Respiratory Syncytial Virus (RSV) Analyst Views
18.
Appendix
19.
About DelveInsight
Key questions answered in the Respiratory Syncytial Virus Pipeline Report
What are the different forms of therapy for Respiratory Syncytial Virus?
How many companies are working on drugs to treat Respiratory Syncytial Virus?
Which drugs from these companies are the most popular?
How many Respiratory Syncytial Virus medicines has each company produced in total?
How many novel therapies for Respiratory Syncytial Virus are currently being developed in the early, mid, and late stages?
How many of the drugs under development can be used alone or in combination with other treatments?
What are the most important industry-industry and industry-academy cooperation, mergers and acquisitions, and licensure practises affecting Respiratory Syncytial Virus?
Related Reports
Acute Respiratory Distress Syndrome Pipeline Insights
Get comprehensive analysis of Acute Respiratory Distress Syndrome pipeline therapies and key companies including Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Bayer, Altor BioScience, among others.
Related Posts
For rich insights into rsv visit, RSV Pipeline Landscape
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/